MarchesiniGMarzocchiRAgostiniFBugianesiE. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol. 2005;16(4):421–427.
2.
McCulloughAJ. Pathophysiology of non-alcoholic steatohepatitis. J Clin Gastroenterol. 2006;40(suppl 1):S17–S29.
3.
TargherGArcaroG. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191(2):235–240.
4.
TargherGBertoliniLPadovaniRZoppiniGZenariLFalezzaG. Associations between liver histology and carotid intima-media thickness in patients with nonalcoholic fatty liver disease. Arterioscler Thromb Vasc Biol. 2005;25(12):2687–2688.
5.
AğaçMTKorkmazLÇavuşoğluG. Association between nonalcoholic fatty liver disease and coronary artery disease complexity in patients with acute coronary syndrome: a pilot study. Angiology. 2013;64(8):604–608.
6.
PalmeriniTCaixetaAGenereuxP. Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: analysis from the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial. Am Heart J. 2012;163(3):383–391.
7.
PalmeriniTGenereuxPCaixetaA. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) trial. J Am Coll Cardiol. 2011;57(24):2389–2397.
8.
GargSGirasisCSarnoGGoedhartD; SYNTAX trial investigators. The SYNTAX score revisited: a reassessment of the SYNTAX score reproducibility. Catheter Cardiovasc Interv. 2010;75(6):946–952.
9.
AkabameSHamaguchiMTomiyasuK. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J. 2008;72(4):618–625.
10.
PundziuteGSchuijfJDJukemaJW. Evaluation of plaque characteristics in acute coronary syndromes: non-invasive assessment with multi-slice computed tomography and invasive evaluation with intravascular ultrasound radiofrequency data analysis. Eur Heart J. 2008;29(19):2373–2381.
11.
SunLLüSZ. Association between non-alcoholic fatty liver disease and coronary artery disease severity. Chin Med J (Engl). 2011;124(6):867–872.
12.
AlperATHasdemirHSahinS. The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome. Turk Kardiyol Dern Ars. 2008;36(6):376–381.
13.
AçikelMSunaySKoplayMGündoğduFKarakelleoğluS. Evaluation of ultrasonographic fatty liver and severity of coronary atherosclerosis, and obesity in patients undergoing coronary angiography. Anadolu Kardiyol Derg. 2009;9(4):273–279.
TargherGBertoliniLPoliF. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005;54(12):3541–3546.
16.
JousilahtiPRastenyteDTuomilehtoJ. Serum gamma-glutamyltransferase, self-reported alcohol drinking, and the risk of stroke. Stroke. 2000;31(8):1851–1855.
17.
SookoianSPirolaCJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol. 2008;49(4):600–607.
18.
KimHCKimDJHuhKB. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis. 2009;204(2):521–525.
19.
TargherGBertoliniLPadovaniR. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2006;29(6):1325–1330.
20.
TargherGBertoliniLPadovaniR. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med. 2006;23(4):403–409.
21.
BrevettiGSchianoVSiricoGGiuglianoGLaurenzanoEChiarielloM. Metabolic syndrome in peripheral arterial disease: relationship with severity of peripheral circulatory insufficiency, inflammatory status, and cardiovascular comorbidity. J Vasc Surg. 2006;44(1):101–107.
22.
JacobsMvan GreevenbroekMMvan der KallenCJ. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest. 2009;39(6):437–444.
23.
ChenJYChouCHTsaiWC. Effects of increased systemic inflammation and central obesity on arterial stiffness in patients with nonalcoholic fatty liver disease. J Am Soc Hypertens. 2012;6(4):253–260.
24.
AthyrosVGKakafikaAIKaragiannisAMikhailidisDP. Do we need to consider inflammatory markers when we treat atherosclerotic disease?Atherosclerosis. 2008;200(1):1–12.
25.
KorhonenPSyvänenKAarnioP. Surrogates of large artery versus small artery stiffness and ankle-brachial index. Int J Angiol. 2011;20(3):167–172.
26.
BrewerLCChaiHSBaileyKRKulloIJ. Measures of arterial stiffness and wave reflection are associated with walking distance in patients with peripheral arterial disease. Atherosclerosis. 2007;191(2):384–390.
27.
MosimannKJacomellaVThalhammerC. Severity of peripheral arterial disease is associated with aortic pressure augmentation and subendocardial viability ratio. J Clin Hypertens (Greenwich). 2012;14(12):855–860.
28.
AthyrosVGTziomalosKGossiosTD; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376(9756):1916–1922.
29.
KatsikiNAthyrosVGKaragiannisAMikhailidisDP. Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial. J Hepatol. 2012;57(2):476.
30.
AthyrosVGTziomalosKKatsikiN; for the GREACE Study Collaborative Group. The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE Study [published online ahead of print November 7, 2012]. Curr Vasc Pharmacol. 2012.
31.
BabuMPaulN. Smoking and NASH: a hidden message from the GREACE trial. J Hepatol. 2012;56(1):300–301.
32.
ZeinCOMcCulloughAJ. Reply to: Smoking and NASH: a hidden message from the GREACE trial. J Hepatol. 2012;56(1):301.
33.
AthyrosVGGioulemeOGanotakisES. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci. 2011;7(5):796–805.
34.
AthyrosVGMikhailidisDPDidangelosTP. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006;22(5):873–883.
35.
AthyrosVGTziomalosKDaskalopoulosGNKaragiannisAMikhailidisDP. Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?Ann Med. 2011;43(3):167–171.
